Other Information.
−Removed: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended December 31, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended March 31, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: On May 12, 2025, Edesa Biotech Research, Inc., a wholly owned subsidiary of the Company, entered into a Consulting Agreement with Stephen Lemieux, the Company’s former Chief Financial Officer (the “Consulting Agreement”), pursuant to which Mr.
+Added: Lemieux has agreed to provide the Company with financial and accounting consulting services for a period of two years, which period may be extended by mutual agreement of Mr.
+Added: Lemieux and the Company.
+Added: In consideration for his services, the Company has agreed to pay Mr.
+Added: Lemieux an hourly rate of CAD $250.00 per hour.
+Added: In addition, pursuant to the Consulting Agreement, Mr.
+Added: Lemieux will be entitled to his fiscal year 2025 bonus, prorated for the seven (7) months in 2025 in which he was employed by the Company as Chief Financial Officer.
+Added: Lemieux will also be entitled to restricted stock units under the Company’s Equity Incentive Plan at the discretion of the Board of Directions.
+Added: The Consulting Agreement is terminable by either party upon thirty days’ prior written notice.
+Added: The foregoing is only a summary of the material terms of the Consulting Agreement and does not purport to be complete.
+Added: The foregoing summary is qualified in its entirety by reference to the complete text of the Consulting Agreement, which is attached hereto as Exhibit 10.4 and is incorporated herein by reference.
EXHIBIT INDEX
−Removed: Amended and Restated Articles of Edesa Biotech, Inc.
−Removed: (included as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on October 31, 2024, and incorporated herein by reference).
Amended Articles of Edesa Biotech, Inc.
(included as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).
−Removed: Form of Warrant (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on October 31, 2024, and incorporated herein by reference).
−Removed: At The Market Offering Agreement, dated October 4, 2024, by and between Edesa Biotech, Inc.
−Removed: Wainwright & Co., LLC (included as Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed on October 4, 2024, and incorporated herein by reference).
−Removed: Securities Purchase Agreement, dated October 30, 2024, between Edesa Biotech, Inc.
−Removed: and Pardeep Nijhawan Medicine Professional Corporation (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on October 31, 2024, and incorporated herein by reference).
Form of Securities Purchase Agreement, dated February 12, 2025, between Edesa Biotech, Inc.
2 unchanged sentences
and the investors signatory thereto (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).
+Added: Employment Agreement, dated April 3, 2025, by and between the Company and Peter Weiler (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on April 4, 2025, and incorporated herein by reference).
+Added: Consulting Agreement, dated May 12, 2025, between Edesa Biotech Research, Inc.
+Added: and Stephen Lemieux (filed herewith).
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
14 unchanged sentences
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: February 14, 2025
EDESA BIOTECH, INC.
2 unchanged sentences
(Principal Executive Officer)
−Removed: February 14, 2025
−Removed: /s/ Stephen Lemieux
−Removed: Stephen Lemieux, Chief Financial Officer
+Added: /s/ Peter Weiler
+Added: Peter Weiler, Chief Financial Officer
(Principal Financial Officer and Duly Authorized Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.